drugset
drugset / Trial / NCT04087525

A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects

NCT04087525 ↗

Phase 1 Completed 31 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics and safety of HIP1701 in healthy subjects.

Timeline

Start
2018-10-23
Primary completion
2018-11-27
Completion
2018-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified — —

Indications

No indication recorded.